Unknown PHASE4 INTERVENTIONAL 3-arm NCT02553083

High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection (HDDT)

Sponsor: Rabin Medical Center

Conditions Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

Interventions Nexium 20 mg Nexium 40 mg amoxicillin 1.5 gr amoxicillin 1gr clarythromicin 500 mg doxycycline 200 mg

Updated 9 times since 2017 Last updated: Jan 29, 2018 Started: Oct 22, 2015 Primary completion: Sep 30, 2020 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02553083, this PHASE4 trial focuses on Bacterial Infection Due to Helicobacter Pylori (H. Pylori) and remains ongoing. Sponsored by Rabin Medical Center, it has been updated 9 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE4

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Recruiting PHASE4
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Feb 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE4

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rabin Medical Center

Data source: Rabin Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Petah Tikva, Israel